Mitral regurgitation (MR) is the abnormal reverse flow of blood in the heart due to leakage through the mitral valve during each heartbeat. A common heart valve disease, MR affects about 5% of the population, and approximately 1% of patients will require medical treatment.
Degenerative MR (DMR) occurs when the valve itself is abnormal. DMR is preferably treated with valve repair.
To provide a safe, effective and non-invasive therapy for all DMR patients with an innovative medical device, thereby addressing a large unmet need in cardiovascular health
Vesalius receives authorization from Health Canada to conduct investigational testing. The Investigational Testing Authorization is for 5 patients at St. Paul's Hospital in Vancouver. This authorization was followed by the...
Dr Peter Skarsgard, Vesalius President and Chief Medical Officer, will be presenting Vesalius TMVr solution twice during the EuroPCR 2024 event held in Paris from May 13th to 17th, 2024. ...
Vesalius Selected as a Top Innovation at PCR London Valves 2023.